| Identification | Back Directory | [Name]
(11β,17β)-11-(1,3-Benzodioxol-5-yl)-17-hydroxy-17-(1-propyn-1-yl)estra-4,9-dien-3-one | [CAS]
189035-07-2 | [Synonyms]
Org34517
Org-34517
SCH900636
Org 34517
SCH-900636
SCH 900636
(11β,17β)-11-(1,3-Benzodioxol-5-yl)-17-hydroxy-17-(1-propyn-1-yl)estra-4,9-dien-3-one
Estra-4,9-dien-3-one, 11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propyn-1-yl)-, (11β,17β)- | [Molecular Formula]
C28H30O4 | [MDL Number]
MFCD07772248 | [MOL File]
189035-07-2.mol | [Molecular Weight]
430.54 |
| Chemical Properties | Back Directory | [Boiling point ]
621.0±55.0 °C(Predicted) | [density ]
1.29±0.1 g/cm3(Predicted) | [solubility ]
Chloroform (Slightly), DMSO (Slightly), Methanol (Sparingly) | [form ]
Solid | [pka]
12.89±0.60(Predicted) | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Uses]
(11b,17b)-11-(1,3-Benzodioxol-5-yl)-17-hydroxy-17-(1-propyn-1-yl)estra-4,9-dien-3-one is a glucocorticoid receptor (GR) antagonists. | [in vivo]
PT150 (30, 100 mg/kg; p.o.; daily for 14 days) shows neuroprotective effects in rotenone (HY-B1756) induced Parkinson’s disease mouse[2]. | Animal Model: | C57Bl/6 mice (2.5 mg/kg/day rotenone by intraperitoneal injection for 14 days)[2] | | Dosage: | 30, 100 mg/kg | | Administration: | P.o.; daily for 14 days | | Result: | Reduced the loss of dopaminergic neuron (DAn) cell bodies in the substantia nigra (SN), but not the striatum, and prohibited intra-neuronal accumulation of α-synuclein (α-syn). |
|
|
|